Alzheimer's as Metabolic Disease ("Type 3 Diabetes")
Multiple — neuroscience and metabolic research · Various (systematic reviews, meta-analyses) (2005)
A growing body of research frames Alzheimer's disease as a metabolic disorder — the brain's inability to use glucose efficiently due to insulin resistance. A meta-analysis of 144 prospective studies found a 1.25-1.91x increased risk of cognitive disorders from insulin resistance. The term "Type 3 diabetes" captures this framing, though it is not officially recognized by WHO or ADA.
Core Concepts
The Problem
Alzheimer's has been primarily understood through the amyloid hypothesis — plaques accumulate and destroy neurons. Decades of drug development targeting amyloid have mostly failed. The metabolic framing offers an alternative: what if the brain is starving for energy because it can't process glucose, and that energy crisis drives the downstream damage?
The Claim
The evidence linking brain insulin resistance to Alzheimer's comes from multiple directions:
**Epidemiology.** A meta-analysis of 144 prospective studies found that insulin resistance increases the risk of cognitive disorders by 1.25- to 1.91-fold. Type 2 diabetics have roughly double the Alzheimer's risk of non-diabetics.
**Mechanisms.** Disruption of brain insulin pathways contributes to amyloid-beta accumulation, tau pathology, and neuroinflammation — the hallmarks of Alzheimer's. The brain becomes unable to efficiently use glucose, its primary fuel.
**Genetics.** The APOE4 gene (the strongest genetic risk factor for Alzheimer's) has been shown to bind more aggressively to insulin receptors on neurons, outcompeting normal APOE3 and blocking the receptor. This provides a molecular link between genetic risk and metabolic dysfunction.
**Alternative fuel.** Ketones can fuel the brain even when glucose metabolism is impaired. This is the basis for ketogenic diet interventions in early Alzheimer's — providing the brain an energy source it can still use.
A 2025 systematic review following PRISMA guidelines synthesized research from 2010-2025 and confirmed the strength of the metabolic link.
Key Evidence
- •Meta-analysis of 144 prospective studies: insulin resistance increases cognitive disorder risk by 1.25-1.91x
- •Type 2 diabetics have approximately double the Alzheimer's risk
- •2025 PRISMA systematic review confirming the metabolic link (studies from 2010-2025)
- •APOE4 protein binds aggressively to neuronal insulin receptors, blocking normal function (2025 Mayo Clinic research)
- •Brain insulin resistance contributes to amyloid-beta accumulation and tau pathology
- •Ketones can fuel the brain when glucose metabolism is impaired — basis for dietary interventions
Practical Implication
Metabolic health may be Alzheimer's prevention. Insulin sensitivity — maintained through exercise, diet, and body composition — could be protective. This reframes dementia from an inevitable neurological fate to a potentially preventable metabolic condition.
Nuance & Limits
"Type 3 diabetes" is a research framing, not a clinical diagnosis — WHO and ADA have not adopted it. It's unclear whether insulin resistance is a primary driver or a secondary effect of neurodegeneration. The amyloid hypothesis hasn't been abandoned. Most researchers see metabolic dysfunction as one contributing factor among several, not the sole cause. Ketogenic interventions for Alzheimer's are still early-stage.
Source Material
Citation Density
Moderate and growing — D'Agostino, Tommy Wood, Attia, and Huberman have all discussed this. The JAMA and PRISMA publications give it serious scientific weight.
Related Ideas
Same metabolic intervention — ketosis — applied to mood vs. neurodegeneration
Exercise improves insulin sensitivity — one of the strongest protective factors against metabolic-driven Alzheimer's